tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate

‌Product Name‌: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate oxalate (Edoxaban Intermediate 2)
‌CAS No.‌: 1210348-34-7

🔬 ‌Product Overview‌
A high-purity pharmaceutical intermediate for synthesizing ‌Edoxaban‌ (CAS 480449-70-5), a ‌direct oral anticoagulant (DOAC)‌ used to prevent stroke and systemic embolism. With ‌≥99% purity‌ (HPLC-certified), it ensures consistency in API manufacturing and compliance with pharmacopeial standards. Suitable for industrial-scale production and R&D of anticoagulant drugs. Available in quantities from ‌1g to 25kg‌ with customizable packaging.

📊 ‌Key Advantages‌
✅ ‌Ultra-High Purity‌: ≥99% (HPLC/GC-tested), minimizing impurities in API batches.
📦 ‌Flexible Supply‌: Bulk packaging (25kg/drum) and lab-scale options (1g–5g) for diverse needs.
💊 ‌Critical Role‌: Key intermediate in Edoxaban synthesis, supporting a $2.8B+ anticoagulant market.

💊 ‌Applications‌

1. ‌API Production‌: Essential for large-scale Edoxaban synthesis.

2. ‌Quality Control‌: Used in impurity profiling and batch validation for regulatory compliance.

3. ‌Generic Drug R&D‌: Accelerates post-patent development of cost-effective anticoagulants.

📜 ‌Quality Certification‌

• ‌Testing Methods‌: HPLC, GC, NMR, and mass spectrometry.

• ‌Compliance‌: Meets ISO 9001 and ICH guidelines for pharmaceutical intermediates.

🌍 ‌Market Trends‌
The demand for Edoxaban intermediates is rising due to ‌patent expirations (2024–2026)‌ and the expansion of generic DOAC markets. The Asia-Pacific region dominates API production, with suppliers offering ‌GMP-compliant intermediates‌ gaining a competitive edge. The global anticoagulant market is projected to grow at ‌7.9% CAGR (2025–2030)‌.